Expanding 177Lutetium-PSMA-617 Use in the Community
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Read More
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
Listen
CAPTURE Trial Reveals BRCA Mutations Linked to Worse Outcomes in mCRPC
Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE trial.
A Deep Dive Into the Evolving Landscape of Prostate Cancer
In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
Inclusion of PSMA-PET to mpMRI May Better Clinical Evaluation of Patients on Active Surveillance
The addition of PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer.
Enzalutamide With or Without Leuprolide Betters Undetectable PSA Rates in CSPC
Treatment with enzalutamide alone and with leuprolide delivered higher rates of undetectable PSA levels compared with leuprolide alone in patients with castration-sensitive prostate cancer.
